Haleon (LON:HLN) Shares Down 0.4% – Here’s Why

Shares of Haleon plc (LON:HLN) fell 0.4% during trading on Thursday . The stock traded as low as GBX 367.10 and last traded at GBX 371.90. 11,338,172 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 200,260,453 shares. The stock had previously closed at GBX 373.50.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a report on Wednesday, November 26th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research report on Friday, October 31st. Berenberg Bank boosted their target price on Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 440 price target on shares of Haleon in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of GBX 420.40.

Haleon Stock Down 0.9%

The business has a 50 day moving average of GBX 368.04 and a two-hundred day moving average of GBX 359.89. The stock has a market capitalization of £32.82 billion, a PE ratio of 22.07, a PEG ratio of 1.49 and a beta of 0.19. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.